Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Biological therapy boosts the immune system to effectively fight melanoma.

Squaric acid dibutylester for alopecia areata can cause benign skin lymphoid growths.

Ruxolitinib cream may help treat severe hair loss in children.

Allergies, especially dust mite allergy, may worsen alopecia areata, and desensitization could help reduce its severity.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Suplatast tosilate successfully treated a woman's systemic sclerosis symptoms.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.

Dupilumab may cause hair loss in some patients with severe atopic dermatitis.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Anti-DFS70 antibodies can help identify nonsystemic autoimmune conditions in SLE patients.

ACTH may be an effective first-line treatment for acute calcium pyrophosphate crystal arthritis.

Secukinumab can cause hair loss, which may improve after stopping the medication.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.

Abrocitinib may effectively treat Lichen Planopilaris.

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

Leflunomide is more likely to help treat alopecia areata than cause it.